Mechanisms of Osimertinib Resistance in EGFR Mutant Lung Cancer

被引：0

作者：

Westover, D. ^{[1
]}

Qiao, H. ^{[1
]}

Ichihara, E. ^{[1
]}

Meador, C. B. ^{[1
]}

Lovly, C. M. ^{[1
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 08期

关键词：

D O I：

10.1016/j.jtho.2017.06.063

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S1546 / S1546

页数：1

共 50 条

[31] Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
Piper-Vallillo, Andrew J.
Sequist, Lecia V.
JACC: CARDIOONCOLOGY, 2019, 1 (02): : 179 - 181
[32] Identification and in silico structural insights of rare recurrent EGFR mutations as resistance mechanisms to osimertinib in EGFR-mutated lung cancer.
Na Zhoutong
Wu, Changling
Lu, Binbin
Cao, Ran
Ma, Yutong
Bao, Hua
Ou, Qiuxiang
Wu, Xue
Shao, Yang
Wang, Zhaoxia
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] Resistance mechanisms against osimertinib in lung adenocarcinoma cells with EGFR-activating mutation
Nishihara, Shigetoshi
Yamaoka, Toshimitsu
Hasebe, Yuki
Ishikawa, Fumihiro
Kusumoto, Sojiro
Ohmori, Tohru
Sagara, Hironori
Yoshida, Hitoshi
Tsurutani, Junjii
CANCER SCIENCE, 2023, 114 : 1494 - 1494
[34] Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
Yang, X.
Zhao, J.
Liang, L.
Xu, L.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S559
[35] Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers
Choudhury, Noura J.
Marra, Antonio
Sui, Jane S. Y.
Flynn, Jessica
Yang, Soo-Ryum
Falcon, Christina J.
Selenica, Pier
Schoenfeld, Adam J.
Rekhtman, Natasha
Gomez, Daniel
Berger, Michael F.
Ladanyi, Marc
Arcila, Maria
Rudin, Charles M.
Riely, Gregory J.
Kris, Mark G.
Heller, Glenn
Reis-Filho, Jorge S.
Yu, Helena A.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : 463 - 475
[36] Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
Lee, Pei-Chih
Fang, Yueh-Fu
Yamaguchi, Hirohito
Wang, Wei-Jan
Chen, Tse-Ching
Hong, Xuan
Ke, Baozhen
Xia, Weiya
Wei, Yongkun
Zha, Zhengyu
Wang, Yan
Kuo, Han-Pin
Wang, Chih-Wei
Tu, Chih-Yen
Chen, Chia-Hung
Huang, Wei-Chien
Chiang, Shu-Fen
Nie, Lei
Hou, Junwei
Chen, Chun-Te
Huo, Longfei
Yang, Wen-Hao
Deng, Rong
Nakai, Katsuya
Hsu, Yi-Hsin
Chang, Shih-Shin
Chiu, Tai-Jan
Tang, Jun
Zhang, Ran
Wang, Li
Fang, Bingliang
Chen, Ting
Wong, Kwok-Kin
Hsu, Jennifer L.
Hung, Mien-Chie
CANCER CELL, 2018, 34 (06) : 954 - +
[37] Phosphoproteomic Analysis Identi fied Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer
Tozuka, Takehiro
Noro, Rintaro
Yoshida, Keisuke
Takahashi, Satoshi
Hirao, Mariko
Matsuda, Kuniko
Kato, Yasuhiro
Nakamichi, Shinji
Takeuchi, Susumu
Matsumoto, Masaru
Miyanaga, Akihiko
Kunugi, Shinobu
Honda, Kazufumi
Adachi, Jun
Seike, Masahiro
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
[38] MEK inhibitor overcomes resistance to osimertinib caused by KRAS mutation in a LMC model of EGFR-mutant lung cancer.
Fukuda, Koji
Takeuchi, Shinji
Otani, Sakiko
Yano, Seiji
CANCER SCIENCE, 2021, 112 : 538 - 538
[39] Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Oxnard, Geoffrey R.
Hu, Yuebi
Mileham, Kathryn F.
Husain, Hatim
Costa, Daniel B.
Tracy, Philip
Feeney, Nora
Sholl, Lynette M.
Dahlberg, Suzanne E.
Redig, Amanda J.
Kwiatkowski, David J.
Rabin, Michael S.
Paweletz, Cloud P.
Thress, Kenneth S.
Janne, Pasi A.
JAMA ONCOLOGY, 2018, 4 (11) : 1527 - 1534
[40] Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, Antonio
Janne, Pasi A.
Mok, Tony
Peters, Solange
NATURE CANCER, 2021, 2 (04) : 377 - 391

← 1 2 3 4 5 →